DAX+0,06 % EUR/USD+0,01 % Gold+0,48 % Öl (Brent)+0,40 %

Rocket PharmaceuticalsAktie

ISIN: US77313F1066 | WKN: A2JA9Q | Symbol: 9IP1
14,500
 
EUR
21.11.19 Tradegate
+1,40 %
+0,200 EUR
Geldkurs 10:51:11
14,400 EUR
280 Stk.
Briefkurs 10:51:11
14,700 EUR
272 Stk.
Mehr Daten anzeigen

Rocket Pharmaceuticals Chart

Neuigkeiten zur Rocket Pharmaceuticals Inc Aktie

ZeitTitel
07.11.19

Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
06.11.19

Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 “Process B” for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting
05.11.19

Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit
24.10.19

Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 “Process A” for Fanconi Anemia
22.10.19

Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
15.10.19

Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress
01.10.19

Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference
23.09.19

 Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
10.09.19

Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine
05.09.19

Rocket Pharmaceuticals Announces First Patient Treated in Phase 1/2 Registrational Trial of RP-L201 for LAD-I
04.09.19

Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting
28.08.19

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
22.08.19

Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia
14.09.17

Avatar CentTrader schrieb:
Genau. Hat sich überschnitten. Hatte mit dem Schreiben angefangen, mußte was anderes …

Insidertrade: :
Hier Upload von Dokumenten / Links zum Wertpapier: Upload

Die neusten Nachrichten zu Rocket Pharmaceuticals

ZeitTitel
07.11.19
Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
06.11.19
Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 “Process B” for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting
05.11.19
Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit
24.10.19
Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 “Process A” for Fanconi Anemia
22.10.19
Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
mehr Rocket Pharmaceuticals Nachrichten »

Nachrichten aus der Branche Pharmaindustrie

ZeitTitel
11:30 Uhr
AKTIE IM FOKUS: Fresenius versuchen Ausbruch aus Seitwärtsphase
11:29 Uhr
AKTIEN-FLASH: Fresenius versuchen Ausbruch aus Seitwärtsphase
11:20 Uhr
AKTIE IM FOKUS: Qiagen wieder nah am Hoch vom Wochenanfang
10:48 Uhr
Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market
10:45 Uhr
Aktie im Fokus - Fresenius SE
mehr Branchennachrichten »

Indexzugehörigkeit von Rocket Pharmaceuticals

WertpapierPerf. %
Nasdaq
-0,24
NASDAQ Biotechnology Index
+0,26
Russell 2000 (calculated by Bridge Data Services)
-0,57
NYSE Biotechnology Index
+0,22
NYSE Biotechnology Index (Total Return)
+0,22
NASDAQ Global Market Composite Index
-0,81
NASDAQ Health Care Index
+0,14
Nasdaq DM Ex Korea Small Cap Index Net Total Return
-0,36
Nasdaq DM Ex Korea Small Cap GBP Index Net Total Return
-0,45
Nasdaq DM Ex Korea Small Cap CAD Index Net Total Return
-0,49
Alle zugehörigen Indizes »

Aktienkurs Rocket Pharmaceuticals A2JA9Q |

BörsenplatzTradegate
Letzter Kurs14,500EUR
Performance+1,40 %
Kurszeit21.11.19
Eröffnung14,500EUR
Tageshoch14,500EUR
Tagestief14,500EUR
Vortageskurs14,500EUR
52-Wochen Hoch17,718EUR
52-Wochen Tief9,870EUR
Performance 1 Monat+17,89 %
Performance 1 Jahr+9,27 %

Stammdaten zu Rocket Pharmaceuticals

NameRocket Pharmaceuticals Inc
KurznameRocket Pharmctc
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA2JA9Q
Symbol9IP1
BranchePharmaindustrie
LandUSA USA
ReferenzwährungUSD
Aktienanzahl50,35 Mio.
Marktkapitalisierung730,05 Mio.EUR

Performance Rocket Pharmaceuticals Aktie

ZeitKursPerf.
1 Tag14,500EUR
+1,40 %
1 Woche13,400EUR
+8,21 %
1 Monat12,300EUR
+17,89 %
3 Monate10,340EUR
+40,23 %
6 Monate15,736EUR
-7,85 %
Lfd. Jahr12,120EUR
+19,64 %
1 Jahr13,270EUR
+9,27 %
3 Jahre24,760EUR
-41,44 %
mehr Performancedaten »
Adresse und Kontaktdaten
NameRocket Pharmaceuticals Inc
StadtLexington, MA
LandUSA USA
Webseitewww.rocketpharma.com
Aktionäre interessieren sich auch für:
#WertpapierPerf. %
1.
Biodelivery Sciences International
+0,44
2.
Neurocrine Biosciences
+0,73
3.
Sanochemia Pharmazeutika
+1,59
4.
Teva Pharmaceutical Industries
-0,11
5.
CytoTools
+0,93
6.
AEterna Zentaris
-2,66
7.
Mologen
+2,89
8.
IntelliPharmaCeutics International
+3,23
9.
IVERIC bio
-2,05
10.
Novavax
+2,38